Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 1/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | KMO | O15229 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27199549 | 0.87 | MAPK1 (0.40) | XIAPBIRC2MAPK1ALDH1A1TSHR | |
| SCHEMBL25757760 | 0.86 | PIK3CD (0.36) | — | |
| SCHEMBL27199328 | 0.78 | ROS1 (0.35) | GPR35MAPK1ALDH1A1TSHRNPC1 | |
| SCHEMBL27199438 | 0.78 | MEN1 (0.40) | XIAPBIRC2MAPK1ALDH1A1TSHR | |
| SCHEMBL27199462 | 0.77 | HTR2A (0.40) | ALDH1A1NPC1RAB9AHTR2AHTR2C | |
| SCHEMBL25757759 | 0.77 | HTR2A (0.34) | HTR2AHTR2C | |
| SCHEMBL27199446 | 0.75 | MAPK1 (0.43) | MAPK1ALDH1A1TSHRNPC1RAB9A | |
| SCHEMBL27199485 | 0.74 | BRD4 (0.38) | MAPK1ALDH1A1TSHRNPC1RAB9A | |
| SCHEMBL27199360 | 0.74 | HTR2A (0.39) | MAPK1ALDH1A1NPC1RAB9AKMO | |
| SCHEMBL27199710 | 0.73 | MAPK1 (0.41) | MAPK1ALDH1A1NPC1RAB9AKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | XIAP 482/4885BIRC2 1058/4885GPR35 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.